- Stock Information
- News & Events
- Analyst Coverage
- Corporate Governance
- Shareholder Services
President and Chief Executive Officer
Dr. Lian serves as our President and Chief Executive Officer, and as a director. Prior to joining Viking Therapeutics, he was a Managing Director and Senior Research Analyst at SunTrust Robinson Humphrey, where he was responsible for coverage of small and mid-cap biotechnology companies with an emphasis on the diabetes, oncology, infectious disease, and neurology spaces. Prior to SunTrust Robinson Humphrey, he was an Executive Director and Senior Biotechnology Analyst at CIBC World Markets, responsible for coverage of mid- and small-cap biopharmaceutical companies. Prior to his career in equity research, he was a research scientist in small molecule drug discovery at Amgen, focused on cancer and endocrine diseases. Prior to Amgen, he was a research scientist at Microcide Pharmaceuticals. Dr. Lian holds an MBA in accounting and finance from Indiana University, an M.S. and Ph.D. in organic chemistry from The University of Michigan, and a BA in chemistry from Whitman College.
Chief Financial Officer
Michael Morneau serves as our Chief Financial Officer. Mr. Morneau has over 20 years of accounting and financial experience at public and private companies in the biotechnology and accounting industries. Prior to Viking, he was VP of Finance and Chief Accounting Officer at Trius Therapeutics, Inc., a subsidiary of Cubist Pharmaceuticals, Inc., a pharmaceutical company, following Cubist’s acquisition of Trius. Prior to Trius, he was Director of Lilly Research Labs Finance at Eli Lilly and Company, a pharmaceutical company. Prior to Eli Lilly, he was Director of Finance and Accounting at SGX Pharmaceuticals, Inc., a biotechnology company, which was acquired by Eli Lilly. Prior to SGX, he was Controller at Momenta Pharmaceuticals, Inc., a biotechnology company. Mr. Morneau earned his MBA and Master of Arts in accounting from New Hampshire College, and a BA in mathematics from the University of New Hampshire.
SVP, Pharmaceutical Development
Hiroko Masamune, Ph.D. serves as our Senior Vice President of Pharmaceutical Development. Dr. Masamune has over 20 years of pharmaceutical development experience. Prior to joining Viking, she was Vice President, Product Development at Aires Pharmaceuticals, Inc., a company focused on developing therapies for pulmonary vascular disorders. Before joining Aires, Dr. Masamune served as Vice President, Product Development at Palkion Inc. At Palkion, she was responsible for all aspects of preclinical development and served as its alliance manager. Prior to Palkion, Dr. Masamune served as a Senior Director, Pharmaceutical Sciences at Neurogen Corp., where she oversaw two Phase 2 candidates for the treatment of insomnia and Parkinson’s disease/restless leg syndrome, one Phase 1 candidate for the treatment of obesity, and a range of early development and late discovery candidates. Previously she spent 14 years in drug discovery and development at Pfizer working in the areas of cardiovascular, pulmonary and infectious diseases. She earned a BS in Organic Chemistry from the University of Wisconsin, and a Ph.D. in Organic Chemistry from the University of California, Los Angeles. Dr. Masamune completed her post-doctoral fellowship in Organic Chemistry at the Massachusetts Institute of Technology.
SVP, Corporate Development
Amy Broidrick serves as our Senior Vice President of Corporate Development. Ms. Broidrick has over 22 years of pharmaceutical industry experience. Prior to joining Viking, she served as Vice President and Head of Global Marketing Excellence and Business Innovation at EMD Serono, Inc, part of Merck KGaA (Germany). Prior to her position at EMD Serono, Ms. Broidrick was Vice President and Head of Marketing and Commercialization at Arena Pharmaceuticals. She has also held roles of increasing responsibility at Merck & Co. and Pfizer (formerly G.D. Searle). Ms. Broidrick is a seasoned industry executive credited with launching and exceeding profit targets for blockbuster brands including Celebrex® in the United States and Zetia® and VYTORIN® (named EZETROL® and INEGY®, respectively in EME&A) across Europe, the Middle East and Africa.
VP, Clinical Development
Dr. Catherine Kelleher serves as our Vice President of Clinical Development. Ms. Kelleher is a skilled biopharmaceutical physician whose experience spans both industry and academia. Prior to joining Viking, Dr. Kelleher served as Vice President of Clinical Development at Coherus BioSciences. Previously, she served as Head of Clinical for the United States at Proteus Digital Health, Inc. Prior to this she worked as a global safety officer for inflammation and oncology and also a clinical research medical director in nephrology at Amgen. Before joining industry, Dr. Kelleher served as Associate Professor of Medicine at the University of Colorado School of Medicine. Her medical training included an internship/residency in internal medicine at Johns Hopkins Hospital, a joint clinical fellowship in nephrology and gerontology at the Harvard teaching hospitals and a post-clinical research fellowship in the Department of Genetics at Harvard Medical School.
VP, Finance and Operations
Greg Zante serves as our Vice President of Finance and Operations. Mr. Zante joins Viking with more than 20 years of accounting and financial experience at public and private companies in the biotechnology and accounting industries. Prior to joining Viking, Mr. Zante was Chief Financial Officer at Dance Biopharm, a diabetes-focused biopharmaceutical company, where he managed the company’s private financing strategy and positioned it for initial public offering activities. Mr. Zante has also previously held senior positions at several biopharmaceutical companies including Sangamo BioSciences, Calyx Therapeutics and Matrix Pharmaceuticals. He is a certified public accountant in the state of California and has previously served as a senior staff accountant at Ernst & Young.